GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT01894360
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT01894022
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01890798
ROTAHALER Device Optimization Study
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01890863
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants
Completed
- Conditions
- TetanusAcellular PertussisDiphtheria
- Interventions
- Other: Retrospective database study using administrative claims data
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01890850
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
Completed
- Conditions
- Pertussis
- Interventions
- Other: Web-based survey questionnaire
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 676
- Registration Number
- NCT01890447
- Locations
- 🇪🇸
GSK Investigational Site, Parla, Spain
Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])
Not Applicable
Completed
- Conditions
- Streptococcus Agalactiae
- Interventions
- Procedure: Blood sampleOther: Vaginal swab sample
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3033
- Registration Number
- NCT01888471
- Locations
- 🇿🇦
GSK Investigational Site, Johannesburg, South Africa
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT01884675
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluarix/Influsplit SSW® (2013-2014 season)
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT01884519
- Locations
- 🇩🇪
GSK Investigational Site, Schmiedeberg, Sachsen, Germany
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluarix/Influsplit Tetra® (2013-2014 season)
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 117
- Registration Number
- NCT01878812
- Locations
- 🇩🇪
GSK Investigational Site, Dresden, Sachsen, Germany
© Copyright 2025. All Rights Reserved by MedPath